The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation (AZALEA-TIMI 71)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04755283
Recruitment Status : Active, not recruiting
First Posted : February 16, 2021
Last Update Posted : March 18, 2024
The TIMI Study Group
Laboratory Corporation of America
Information provided by (Responsible Party):
Anthos Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : December 14, 2023
Estimated Study Completion Date : January 2025